|
AFG3L2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
4.180300E-02 |
| Normal-vs-Stage3 |
1.11022302462516E-16 |
| Normal-vs-Stage4 |
1.62458935193399E-12 |
| Stage1-vs-Stage2 |
6.426400E-04 |
| Stage1-vs-Stage3 |
3.810000E-01 |
| Stage1-vs-Stage4 |
4.543700E-02 |
| Stage2-vs-Stage3 |
2.588400E-04 |
| Stage2-vs-Stage4 |
2.09999999999377E-05 |
| Stage3-vs-Stage4 |
2.162800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
5.23850000044845E-07 |
| Normal-vs-Asian |
2.59969823446227E-12 |
| Caucasian-vs-AfricanAmerican |
3.713400E-01 |
| Caucasian-vs-Asian |
6.125800E-01 |
| AfricanAmerican-vs-Asian |
2.681200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.85771406538515E-13 |
| Normal-vs-Female |
1.62470037423645E-12 |
| Male-vs-Female |
9.655400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
1.48769885299771E-14 |
| Normal-vs-Age(61-80Yrs) |
2.69690000331835E-08 |
| Normal-vs-Age(81-100Yrs) |
6.42509999999596E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.186400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.317850E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.319800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.236400E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.068400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.452400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.785100E-04 |
| Classical-VS-Follicular |
2.74399999999897E-06 |
| Classical-VS-Other |
6.023600E-01 |
| Classical-VS-Normal |
1.6242562850266E-12 |
| Tall-VS-Follicular |
1.00209995856915E-09 |
| Tall-VS-Other |
6.250000E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
7.434300E-02 |
| Follicular-VS-Normal |
6.394900E-04 |
| Other-VS-Normal |
5.9428000000028E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.22250012732661E-11 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
3.83990000019097E-07 |
|
|
